Navigation Links
WuXi PharmaTech Announces Second Quarter 2007 Results
Date:9/5/2007

- Net Revenues Up 99% Year-Over-Year

SHANGHAI, China, Sept. 5 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) ("WuXi PharmaTech" or "the Company"), the leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its unaudited financial results for the second quarter ended June 30, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Second Quarter 2007 Highlights:

-- Total net revenues increased 99.3% over the second quarter of 2006 to

US$30.2 million.

-- Net income increased 482.1% over the second quarter of 2006 to US$7.1

million.

-- Diluted earnings per American Depositary Share ("ADS") for the second

quarter of 2007 was US$0.11. Diluted earnings per ADS excluding share-

based compensation expenses (non-GAAP) for the second quarter of 2007

was US$0.13.

"During the second quarter of 2007, we experienced strong revenue and earnings growth compared to the same period last year," said Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "We achieved solid growth throughout our business divisions, with revenue from laboratory services up 102.1% and revenue from research manufacturing up 86.8%. In the second quarter of 2007, laboratory services remained the major revenue contributor, accounting for 83.1% of our total net revenues, with research manufacturing accounting for the remainder. Our strong revenue growth was driven by the robust demand for drug R&D outsourcing services that we provide, and was a direct result of our ability
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... Clinical Trial Application (CTA) with the United ... seeking regulatory approval to initiate clinical trials for the ... Contingent on the Company receiving CTA regulatory approval, ... to assess the safety, tolerability and dose escalation of ...
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell therapies, ... the University of Calgary in conjunction with co-authors from ... further validates the company,s ongoing clinical research using dermal ... pattern baldness. The paper entitled " Hair ...
(Date:12/22/2014)... December 22, 2014 The ... publication of original research, reviews and editorials addressing ... clinical practice, today published a provocative article exploring ... development, progression and potential treatment of prostate cancer. ... research and proposes the possibility that there could ...
(Date:12/19/2014)... 19, 2014 Charm Sciences is pleased ... the Detection of Aflatoxin M1 in raw commingled milk ... third party validation. The peer reviewed report of the ... Institute for Agricultural and Fisheries Research (ILVO-T&V) has been ... Aflatoxin B1, the most toxic aflatoxin and a known ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... 2 Sanofi-aventis announced,today that one year ... STEEPLE,studies confirm clear net clinical benefit for ... for Lovenox(R) vs,Unfractionnated Heparin (UFH). The ... were presented during,hotline sessions at the European ...
... Researchers at the National Institute of Standards ... calibration tools to help correct and validate ... substances based on fluorescence. , Recent ... the development and use of fluorescence-based analytic ...
... governments biodefense efforts, the potential for terrorists to cause ... years after the letter attacks that shook the nation ... University of Michigan Medical School have developed the first ... inside unwitting immune cells their supposed attackers ...
Cached Biology Technology:New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 2New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 3New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 4New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 5Fluorescent glass SRMs are new tool for spectroscopy 2Taming the anthrax threat 2Taming the anthrax threat 3
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 /PRNewswire/ ... ) has announced the addition of the ... report to their offering. ... This insight provides an overview of the ... Watermarking aims to control and monitor piracy ...
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... July 2012, Apple introduced the fingerprint reading feature ... only device of Apple incorporating such a feature, ...
(Date:12/19/2014)... Calif. , Dec. 18, 2014  23andMe, Inc., ... of a study that pinpoints fine-scale differences in genetic ... States . Since immigrants first arrived ... United States has served as a meeting ... how American history and the ongoing mixing of peoples ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... living sensor that can spot contamination. They have also ... even in previously untreatable cold areas, microbiologists heard today ... Microbiology,s Autumn meeting being held this week at Trinity ... in the sub-arctic. It contains over 230,000 tonnes of ...
... a new method to fabricate borosilicate glass ... nanoparticles are more stable when subjected to ... currently used nanoparticles made of polymers or ... range of potential nanoparticle applications in biomedical, ...
... MD The Biophysical Society is pleased to announce ... recipients will receive their awards at the Society,s 53rd ... Boston Convention and Exhibitions Center in Massachusetts. The awardees ... California, San Francisco, will receive the Anatrace Membrane Protein ...
Cached Biology News:Living sensor can warn of arsenic pollution 2Biophysical Society names 2009 award recipients 2
...
The Holten Horizontal series of laminar airflow work benches offers comfort and ease of use....
... Fixed Angle Polypropylene Rotor designed for ... Centra CL3/CL3R** and Centra-MP4/MP4R*. A translucent ... /MP4, ,EXCLUSIVE polypropylene rotor design provides ... repeatedly autoclaved. Polypropylene rotors are ...
... Forma stacking shakers have the ... speed stacked 3-high, and the ... sensitive "soft shake" applications. ... and systems, our stackers are ...
Biology Products: